 Citigroup raised the price target on Ardelyx Inc NASDAQ:ARDX to 13 from 7, with a Buy rating unchanged. The update follows the Companys plans to launch Ibsrela tenapanor for irritable bowel syndrome with constipation IBS-C independently in Q2 2022. 